Related by context. All words. (Click for frequent words.) 67 PCA3 test 67 HERmark 66 Cervista HPV HR 65 NMP# 65 Epigenomics proprietary 65 HER2 expression 64 CIN2 + 64 Septin9 64 TMPRSS2 ERG 64 PROLARIS 63 specific antigen PSA 63 APTIMA HPV 63 miRview mets 63 miRview ™ squamous 63 Septin 9 63 qRT PCR 62 antigen PSA 62 Lp PLA 2 62 immunohistochemical analysis 62 OVA1 62 eTag assays 62 ELISPOT 62 DNA methylation biomarkers 62 anti JCV antibodies 61 MammaPrint R 61 methylated DNA 61 endoglin 61 immunohistochemical 61 HGPIN 61 prostate cancer CaP 61 serum prostate 61 NPM1 61 sarcosine 61 carcinoembryonic antigen 61 PreGen Plus 61 VeriStrat 60 NGAL 60 B7 H3 60 promoter methylation 60 urine cytology 60 skin sterol 60 chlamydial infection 60 Lp PLA2 60 miRview squamous 60 PCA3 gene 60 miRview ™ mets 60 Mammostrat 60 T SPOT.TB 60 microRNA biomarkers 60 Corus CAD 60 biomarker 60 PSP# [002] 60 p# biomarker 60 immunochemical 60 KRAS mutation 60 GSTP1 60 mSEPT9 60 OnDose 60 Hexvix 60 HER2 positive cancers 60 BRAF mutation 60 PCa 59 APTIMA HPV assay 59 predictive biomarker 59 Oncotype DX colon cancer 59 Oncotype DX breast cancer 59 Trofile 59 ColonSentry ™ 59 HPV# 59 Ki# 59 NMP# BladderChek Test 59 Prostate Specific Antigen 59 Her2/neu 59 Prostate Specific Antigen PSA 59 Recurrence Score 59 P2V TM 59 ELISpot 59 Cervista HPV 59 KRAS mutations 59 serum PSA 59 rs# [002] 59 co receptor tropism 59 cardiac troponin T 59 WT1 58 #F FDG PET 58 SNP rs# [001] 58 K ras mutations 58 serologic 58 CaP 58 hc2 58 cystatin C 58 estrogen receptor ER 58 axillary lymph nodes 58 HAAH 58 peripheral blood mononuclear 58 PCA3 assay 58 Immunohistochemistry 58 PCA3 prostate cancer 58 FLT3 58 microsatellite instability 58 breast carcinoma 58 HER2 gene 58 hsCRP 58 XmAb# 58 epithelial tumors 58 TIMP 1 58 EpCAM 58 BRAF V#E mutation 58 PCA3 scores 58 Antigen CEA 58 AspirinWorks 58 specific antigen 58 prostate specific 58 EUS FNA 58 Chronix 58 HERmark assay 58 Hybrid Capture 58 immunohistochemical staining 58 NADiA 58 PITX2 58 Trofile assay 58 Cervista 58 TGFBR1 * 6A 58 EGFR mutations 58 ERCC1 58 KRAS variant 58 MTWA 57 A2 Lp PLA2 57 CTAP# Capsules 57 genotypic 57 IL#B 57 MammaPrint 57 AlloMap 57 Oncotype DX ® 57 FDG PET 57 A3 adenosine receptor 57 Clusterin 57 nomograms 57 MDRD equation 57 variant allele 57 VKORC1 57 HER2 positive metastatic breast 57 mesothelin 57 UroVysion 57 guaiac 57 ThinPrep Pap Test 57 Oncotype DX Recurrence Score 57 Previstage TM GCC 57 RECAF 57 colorectal carcinomas 57 advanced adenomas 57 MGd 57 OncotypeDX 57 Digital Mammographic Imaging 57 RRM1 57 Immunohistochemical staining 57 microRNA expression 57 sDNA 57 situ hybridization 57 quantitative gene expression 57 Prostate specific antigen 57 K RAS 57 ImmuKnow 57 BRACAnalysis 57 Trofex 57 Oncotype DX 57 histopathologic 57 NSCLC tumors 57 thyroglobulin 57 FDG-PET/CT 57 RT qPCR 57 pancreatic adenocarcinoma 57 assay detects 57 PLCO 57 Prostate Lung Colorectal 57 EarlyCDT Lung 57 HER-2/neu 57 rs# [004] 57 miRs 57 ErbB2 positive 57 TMPRSS2 ERG fusion 57 lymph node metastases 57 KRAS status 57 cystatin 57 splice variants 57 IGF IR 57 F FDG PET 57 NADiA ProsVue 57 clusterin 56 DNA methylation biomarker 56 HCV antibody 56 florbetaben 56 K ras 56 Prognostic 56 Onko Sure TM 56 MAGE A3 56 antigen PSA levels 56 PCR assay 56 immunochemical fecal occult 56 OMP #M# 56 immunohistochemistry IHC 56 Genotypic 56 ASCUS 56 LEUKINE 56 Aurora kinase 56 cytokeratin 56 maternal serum 56 MDR1 56 ResponseDX Lung ™ 56 molecular diagnostic assay 56 protein biomarkers 56 cTnT 56 FullTerm 56 clinico pathological 56 LungAlert TM 56 pCR 56 multivariate logistic regression 56 heparanase 56 fluorodeoxyglucose positron emission tomography 56 AlzheimAlert TM 56 HIFU therapy 56 everolimus eluting stent 56 Azedra 56 Azedra ™ 56 Epidermal Growth Factor Receptor 56 Screening Trial 56 DNA methylation markers 56 Cologuard 56 LungExpress Dx TM 56 miRview meso 56 Radient Pharmaceutical current 56 CA9 SCAN 56 secretory phospholipase A2 sPLA2 56 GPx 56 RQ PCR 56 breast cancer subtypes 56 ACRIN 56 serum biomarkers 56 UGT#A# 56 lobular carcinoma 56 TOP2A 56 HPV genotypes 56 prostate carcinoma 56 Immunohistochemical analysis 56 tumorigenicity 56 prognostic markers 56 XIENCE V PROMUS Stent 56 castration resistant prostate cancer 56 EGFR HER 56 metastatic neuroendocrine tumors 56 NicAlert 56 quantitative PCR 56 genotypic resistance 56 HER2/neu 56 immunostaining 56 Epi proColon 56 vitro assay 56 locoregional recurrence 56 5alpha reductase 56 mammographic density 55 ductal cancer 55 throughput RNAi 55 TLE3 55 AtherOx 55 eIF4E 55 p# antigen 55 AxSYM 55 T SPOT.TB test 55 Oncotype 55 tumor hypoxia 55 transrectal ultrasound guided 55 EGFR HER2 55 biochemical recurrence 55 methylation markers 55 myeloperoxidase 55 mRNA expression 55 ColonSentry TM 55 undetectable HBV DNA 55 Immunoassay 55 elotuzumab 55 cervical intraepithelial neoplasia 55 Neisseria gonorrhoeae 55 FGFR2 55 intima media thickness 55 prognostic variables 55 Immunohistochemistry IHC 55 diagnostic biomarker 55 eosinophil count 55 Epigenomics 55 Roche AmpliChip 55 soluble CD# ligand 55 BladderChek Test 55 LTBI 55 D dimer 55 C. pneumoniae 55 bivariate analysis 55 cytological 55 JAK2 55 EGFR mutation 55 reagent kit 55 situ LCIS 55 ResponseDX Lung TM 55 KRAS mutation status 55 hypermethylated 55 gene loci 55 microarray gene expression 55 pretargeting 55 Affymetrix microarray technology 55 NuroPro R 55 colorectal cancer CRC 55 pT3 55 inflammatory biomarkers 55 pharmacokinetic PK 55 obstructive coronary artery 55 acid phosphatase PAP 55 ResponseDX 55 microvessel density 55 STRIDE PD 55 CC genotype 55 Fludara ® 55 grade cervical intraepithelial 55 VerifyNow 55 genetic biomarkers 55 NMP# R 55 metastatic prostate 55 CCX# 55 HER3 55 BladderChek 55 NimbleGen arrays 55 multivariate Cox 55 Inhibin B 55 CALGB 55 oral FTY# 55 multivariate regression analysis 55 Logistic regression 55 hepatitis C HCV 55 progesterone receptor PR 55 Amplimexon 55 EDEMA3 55 DiagnoCure 55 plasma pharmacokinetics 55 hTERT 55 EOquin TM 55 BiTE 55 Septin9 biomarker 55 viral kinetics 55 mITT population 55 Coronary calcium 55 YONDELIS 55 ImmuKnow assay 55 gefitinib Iressa 55 pharmacodynamic effects 55 mSEPT9 biomarker 55 miR #a [002] 55 Immunotherapeutic 55 PITX2 methylation 55 Cystatin C 55 miRNA biomarkers 55 biodistribution 55 Anticalin ® 55 miRNA expression 55 galiximab 55 ALTROPANE 55 ELACYT 55 histological subtype 55 HuMax 55 vimentin 55 anti CD# antibodies 55 SERMs 55 Elocalcitol 55 inhibin 55 PSADT 55 PIK3CA 55 Cardiotoxicity 55 univariate 55 VerifyNow P#Y# 55 multiplexed assays 55 ResponseDX Colon ™ 55 intact parathyroid hormone 55 nomogram 55 BRACAnalysis ® 55 serum biomarker 55 diagnostic assays 55 HOMA IR 55 tPSA 55 mRCC 55 rNAPc2 55 hypermethylation 55 SYNTAX trial 55 ABCSG 55 Symadex 55 tumor specific antigen 55 pharmacodynamic properties 54 quantitative RT PCR 54 telomerase activation 54 histologies 54 prostate biopsy 54 NT proBNP 54 multivariate analyzes 54 LungExpress Dx 54 ERBB2 54 HER2 overexpression 54 prognostic significance 54 Getzenberg 54 genetic polymorphisms 54 HG PIN 54 microRNA profiling 54 viral tropism 54 Telatinib 54 HBsAg 54 vitro experiments 54 DCE MRI 54 univariate analysis 54 urothelial carcinoma 54 molecular subtypes 54 MAbs 54 lymph node metastasis 54 KRAS oncogene 54 apolipoproteins 54 differentially expressed genes 54 micrometastasis 54 prognostic marker 54 coinfected patients 54 epithelial ovarian cancer 54 SLN biopsy 54 HPV-#/# 54 dehydroepiandrosterone sulfate 54 delta isoform 54 elevated CRP 54 eIF 4E 54 C Reactive Protein 54 CINtec ® PLUS 54 tumor xenograft models 54 GAMMAGARD 54 Xanafide 54 OncoMethylome 54 pT2 54 Prognostic Value 54 sensitivity specificity 54 predictive biomarkers 54 prostate cancer PCa 54 interobserver agreement 54 NADiA TM 54 ENMD # 54 MAGE A3 ASCI 54 EchoCRT 54 Leydig cell 54 S#A# [002] 54 PRESEPT 54 coronary artery calcium 54 seropositivity 54 NMP# assay 54 gene amplification 54 relapsed MM 54 AppyScore 54 HOXB# 54 μmol L 54 FCGR3A 54 micrometastases 54 Gene Expression Assays 54 T#I [002] 54 sPLA2 54 INTERCEPT platelets 54 thyrotropin 54 lupus anticoagulant 54 ovarian pancreatic 54 mertansine 54 invasive carcinomas 54 prostate specific antigen 54 Third Eye Retroscope 54 MSMB 54 immunoblotting 54 virulence genes 54 antitumor effect 54 prognostic 54 preclinically 54 SPINK1 54 HER2 receptor 54 definite stent thrombosis 54 Subgroup analysis 54 EphB4 54 prognostic indicator 54 ARB telmisartan 54 biomarkers 54 platelet reactivity 54 atypical hyperplasia 54 DAS# CRP 54 GFT# 54 radiotherapeutic 54 logistic regression analyzes 54 peptide antigens 54 miRview TM mets 54 ABCB1 54 Alternans 54 FDG uptake 54 F FLT 54 galectin 3 54 trabectedin 54 breast carcinomas 54 Natalizumab 54 deCODE ProstateCancer TM 54 fine needle aspiration 54 BRAF mutations 54 independent prognostic marker 54 Tr DNA 54 apolipoprotein B 54 biopsied tissue 54 transcriptomic 54 Vitro Diagnostic IVD 54 fluoroquinolone resistance 54 undergone radical prostatectomy 54 elevated LDH 54 CIN3 54 hepatocellular carcinoma 54 OVA1 ® 54 IgG antibodies 54 PD2i ® 54 microdeletions 54 ZD# [001] 54 HCV SPRINT 54 echocardiographic parameters 54 HER2 ErbB2 54 Factor VIIa 54 SABCS 54 Pharmacogenetic 54 C. trachomatis 54 DNA methylation patterns 54 estimated GFR 54 BCIRG 54 microalbuminuria 54 ResponseDX ™ 54 genomic loci 54 detecting colorectal cancer 54 genomic alterations 54 CINtec R 54 immunoglobulin G 54 Annexin V 54 interleukin IL -# 54 Multiple logistic regression 54 pharmacogenetic 53 WavSTAT 53 Screening Trial DMIST 53 microarray experiments 53 TCF#L# 53 MassARRAY platform 53 transcriptome sequencing 53 neratinib 53 FDG PET imaging 53 rEEG 53 miRview ® 53 S. maltophilia 53 HTS assay 53 SNP genotyping 53 advanced adenoma 53 renal tumors 53 lipoprotein associated phospholipase 53 endometrial ovarian 53 trastuzumab Herceptin 53 RTOG 53 cell adhesion molecule 53 murine models 53 TPMT 53 Subgroup analyzes 53 reticulocytes 53 subgroup analyzes 53 Onko Sure ® 53 renal cell carcinomas 53 clinically localized prostate 53 mtDNA mutations 53 troponin T 53 transgene expression 53 mutational analysis 53 VivaGel ™ 53 vidofludimus 53 advanced neoplasia 53 Glycominds 53 PGxHealth FAMILION 53 rs# [001] 53 BCG refractory 53 MGUS 53 Digene HPV Test 53 Flow cytometry 53 serum protein biomarkers 53 SUVmax 53 serum ferritin 53 Aplidin 53 oncologic outcomes 53 IV bisphosphonates 53 methylmalonic acid 53 TASQ 53 albumin excretion rate 53 goserelin 53 HE4 53 EGFR TKIs 53 qualitative serum 53 ATL# [001] 53 cardiac troponin 53 latent tuberculosis infection 53 genes CYP#C# 53 depsipeptide 53 hepatocellular carcinomas 53 AGHD 53 hepatoma 53 xCELLigence System 53 pDCs 53 antibody titer 53 VeraTag assays 53 pain palliation 53 CellPort Technologies 53 malignant pleural mesothelioma 53 gene expression profiling 53 IFN α 53 miR #b [002] 53 deCODE AF TM 53 HIV1 53 miR #a [001] 53 histological subtypes 53 colorectal tumor 53 lymphovascular invasion 53 SmartChip System 53 miRview TM squamous 53 aggregated Abeta 53 scintigraphic 53 susceptibility loci 53 Agilent microarrays 53 E. faecalis 53 HER1 53 RE LY 53 LHRH receptor positive 53 Zevalin consolidation 53 SmartChip TM Real 53 enzyme immunoassay EIA 53 gastric adenocarcinoma 53 prospective multicentre 53 amplified nucleic acid 53 xMAP Technology 53 Pearson correlation coefficients 53 HLA DRB1 * 53 nonsmall cell lung cancer 53 Alkaline Phosphatase 53 Her2 53 kidney allograft 53 VeraTag 53 molecular biomarkers 53 differential gene expression 53 nodal metastasis 53 OnDose TM 53 colorectal lung 53 MassARRAY 53 Breast Cancer Assay 53 genomewide 53 folate receptor 53 multivariable analysis 53 Pharmacodynamic 53 genitourinary cancers 53 TIMP 53 RNase L 53 ELISA kit 53 histopathologic examination 53 Immunoassays 53 cytologic 53 Sanger Sequencing 53 PROCLEIX ULTRIO assay 53 GAP #B# 53 node metastases 53 sustained virological response 53 Osteopontin 53 gene polymorphisms 53 AEG# 53 bcl 2 53 nucleic acid amplification 53 RT PCR assay 53 midkine 53 HER2 negative 53 ERalpha 53 Velcade bortezomib 53 androgen receptor AR 53 NCCN guidelines 53 interferon IFN 53 HLA DQ2 53 ovarian carcinoma 53 synovial tissue 53 annexin V 53 PGxPredict 53 AEGR 53 CXCR4 53 progesterone receptor 53 prognostic biomarker 53 BCR ABL mutations 53 Zolinza 53 xenograft models 53 D Dimer 53 glycosylated 53 lentiviral 53 PLAC Test 53 clinicopathological features 53 mammographically 53 NicAlert TM 53 KRAS BRAF 53 COR Analyzer 53 inotropic 53 immunohistochemistry 53 extracolonic findings 53 EndoTAGTM 1 53 PlGF 53 H pylori 53 aT cell 53 multiplex PCR 53 Haptoglobin 53 MSH2 53 thymidylate synthase TS 53 favorable pharmacokinetic profile 53 reagent kits 53 mutated K ras 53 myeloproliferative disorders 53 β amyloid 53 UVIDEM 53 tissue microarray 53 transfection reagents 53 cervical cytology 53 oral Xeloda 53 therapeutic monoclonal antibody 53 Meta analyzes 53 proton MR spectroscopy 53 histopathological 53 IRX 2 53 S. aureus isolates 53 QTinno 53 Histologic 53 ChemoFx ® 53 MAPK pathway 53 AMACR 53 Doxil ® 53 molecular biomarker 53 #F FDG 53 serum estradiol 53 PROGENSA R 53 hematological parameters 53 product ColonSentry TM 53 precursor lesions 53 Anticalins ® 53 multicenter randomized clinical 53 CTNNB1 53 ALK mutations 53 JAK1 53 Æterna Zentaris 53 Kaplan Meier analysis 53 lactate dehydrogenase LDH 53 CNS LS 53 noninferiority 53 iNOS 53 plasma lipid 53 vitro ADME 53 azacytidine 53 TNFa 53 BRAF V#E 53 molecular diagnostic tests 53 malignant lesions 53 ptau 53 somatic mutations 53 cediranib 53 dose Iluvien 53 K#R [002] 53 RE LY trial 53 Squamous 53 serum phosphorous 53 risk stratification 53 PSA kinetics 53 effector function 53 tumor subtypes 53 percutaneous biopsy 53 gene expression microarray 53 Octreolin 53 enzastaurin 53 OvPlex ™ 53 cobas 53 Radical prostatectomy 53 heterozygotes 53 CDKN2A 53 ARCHITECT HIV 53 DNA methyltransferases 53 EAA TM 53 SIR Spheres 53 sCJD 53 HE4 test 53 epoetin alpha 53 surgically resected 52 BRCA2 mutation carriers 52 RPC Onko Sure 52 protein tyrosine phosphatase 52 activin 52 miRNA molecules 52 Reynolds Risk Score 52 SLC#A# [002] 52 abnormal Pap 52 RhuDex ® 52 IGFBP 52 Degarelix 52 MGMT gene 52 HER2 neu 52 ExTRACT TIMI 52 Shc 52 Protelos R 52 PDGFR 52 multicentre randomized 52 rheumatoid factor 52 Exelixis compounds 52 TLR9 agonists 52 Multivariate analysis 52 MMSE score 52 CCR5 receptor antagonist 52 carotid bruit 52 malignant nodules 52 metabolomic profiling 52 glycan structures 52 HPV subtypes 52 AST ALT 52 kidney urologic 52 diaDexus 52 PreDx 52 CYP#D# 52 multigene expression test 52 APTIMA 52 ChemoFx 52 colorectal adenoma 52 conditional logistic regression 52 hemagglutination inhibition 52 NuroPro ® 52 NMIBC 52 abnormal cytology 52 CyPath ® assay 52 Affymetrix GeneChip ® 52 Coronary artery calcium 52 Diabetes Risk Score 52 PTPN# 52 CIN3 + 52 atypia 52 lactate dehydrogenase 52 ovarian breast 52 univariate analyzes 52 E#F# 52 cDNAs 52 selective inhibition 52 gene methylation 52 RE LY ® 52 serine protease 52 EDEMA3 trial 52 myocardial necrosis 52 xTAG Cystic Fibrosis 52 Onconase 52 bFGF 52 GPC3 52 comparative genomic hybridization 52 beta actin 52 viral kinetic 52 distant metastasis 52 allelic 52 CYT# potent vascular disrupting 52 diagnostic prognostic 52 adenoviral 52 lymphocyte counts 52 FAMILION 52 colorectal neoplasia 52 nonmetastatic 52 PARP inhibition 52 multi analyte 52 exhaled nitric oxide 52 Amplicor 52 multiplex assay 52 Treg cell 52 logistic regression models 52 cTnI 52 ImmunoCyt TM uCyt + 52 colorectal carcinoma 52 LSIL 52 leukocyte count 52 Orazol 52 EphA2 52 TNFR1 52 FGFR4 52 prospectively defined 52 Teysuno 52 Framingham Risk Score 52 tHcy 52 apolipoprotein AI 52 EGFR mutation status 52 microarray analysis 52 VMAT2 52 intraobserver 52 cervical carcinoma 52 AVADO 52 perfusion imaging 52 low expressors 52 situ hybridization FISH 52 GenPath 52 HIF PH inhibitors 52 #.#ng/ml 52 Molecular Biometrics 52 peptide BNP 52 proteomic analysis 52 metastatic lymph nodes 52 ultrastructural 52 coronary calcium 52 hs CRP 52 coronary stenosis 52 genotype 1a 52 SensiGene 52 ParAllele 52 ALCL 52 kallikrein 52 flavopiridol 52 CEACAM1 52 Sanger sequencing 52 Viatronix V3D Colon 52 BladderChek R 52 Mass Spectrometry MS 52 Estrogen Receptor 52 ABLAVAR ™ 52 APOE e4 52 SNP rs# [002] 52 histologic diagnosis 52 postmenopausal osteoporotic women 52 HCV infections 52 Oncotype Dx 52 PDGF receptor 52 genomic biomarker 52 LSI #P 52 cell lysate 52 transient elastography 52 anti CD3 52 gemcitabine Gemzar 52 linkage disequilibrium 52 alanine aminotransferase ALT 52 xTAG RVP 52 PNA FISH TM 52 Vitro Diagnostic 52 cytoreductive nephrectomy 52 baseline LDH 52 cytogenic 52 reaction RT PCR 52 serotonin synthesis 52 seminoma 52 HBV genotype 52 Estradiol 52 single nucleotide polymorphism 52 LRP5 52 OvaRex MAb 52 peritoneal carcinomatosis 52 MEK inhibitors 52 AdnaGen 52 CLIA certified laboratories 52 trastuzumab emtansine T DM1 52 squamous 52 T1c 52 whole genome genotyping 52 prostatic adenocarcinoma 52 myocardial perfusion 52 ELISA enzyme 52 #T# L1 52 PSA velocity 52 SLNB 52 alkaline phosphatase ALP 52 Wilcoxon rank sum 52 MTHFR 52 methylation patterns 52 immunoblot 52 alvespimycin 52 NMP# BladderChek 52 PSA nadir 52 PD2i ® nonlinear algorithm 52 RBP4 52 Rosetta Genomics microRNA 52 molecular diagnostic assays 52 enzyme immunoassay 52 Upregulation 52 PROactive study 52 interferon γ 52 sequence homology 52 Solid Tumors 52 tipranavir r 52 NuroPro 52 gastric carcinoma 52 histone deacetylase HDAC inhibitor 52 Hemoccult II 52 TAXUS Liberte Stent 52 pro angiogenic 52 DNAWitness Y 52 cMET 52 Pharmacokinetic parameters 52 CDK inhibitor 52 RhD 52 Alferon LDO 52 mucinous 52 IGF 1R 52 bladder carcinoma 52 oncogenic HPV 52 IDH1 52 TTR gene 52 interobserver